Best Peptides for Muscle Growth
Research peptides studied for muscle growth and body composition work primarily through the growth hormone-IGF-1 axis, which drives protein synthesis, satellite cell activation, and lean mass preservation. This guide ranks the most studied GH secretagogues and IGF-1-related compounds by evidence quality and mechanism clarity, drawing on published pharmacodynamic and body composition research.
CJC-1295 plus Ipamorelin is the most studied GH secretagogue combination, with published Phase 2 pharmacodynamic data on GH and IGF-1 elevation and small human body composition studies. Tesamorelin has the strongest regulated human evidence for body composition, with FDA approval specifically for HIV-associated lipodystrophy. IGF-1 LR3 has a direct anabolic mechanism but carries the least human safety data. None of these compounds are approved for muscle growth or athletic performance.
Muscle & Performance · Evidence Map
Best Peptides for Muscle Growth
5 compounds ranked · Updated July 2026
A long-acting GHRH analogue plus selective secretagogue used to study GH-axis signaling and body composition endpoints
- Dose
- Research-study protocols vary; not dosing guidance
- Half-life
- CJC DAC: ~8 days; Ipamorelin: ~2 hours
A direct IGF-1 receptor agonist used to study anabolic signaling pathways
- Dose
- Research-study protocols vary; not dosing guidance
- Half-life
- ~20-30 hours
A well-defined example of indication-specific GH-axis evidence with controlled human data
- Dose
- Approved-product dosing is indication-specific and clinician-directed; not a research-use protocol
- Half-life
- ~26 minutes
A non-selective ghrelin-receptor agonist for GH-pulse pharmacodynamic research
- Dose
- Research-study protocols vary; not dosing guidance
- Half-life
- ~15-60 minutes
The GHRH analog with the most established clinical safety record from its prior prescription history
- Dose
- Research-study protocols vary; not dosing guidance
- Half-life
- ~10-20 minutes
What Muscle Growth Peptide Research Actually Shows
- 1GH secretagogues do not build muscle directly. They amplify GH pulses, which raises IGF-1 over hours to days, which then activates IGF-1 receptors on muscle satellite cells to signal protein synthesis. The muscle anabolic effect is two mechanistic steps removed from the peptide itself. This chain means that individuals with blunted GH axis response or low baseline IGF-1 may see substantially different results.
- 2The published pharmacodynamic literature for GH secretagogues consistently controls for insulin levels because post-prandial insulin elevation triggers somatostatin secretion, which inhibits GH pulse amplitude. This explains why published pharmacodynamic studies standardise subjects' metabolic state. Interpreting GH pulse data from these studies requires understanding that the reported amplitudes reflect those controlled conditions, not free-living variation.
- 3Combining three or more GH secretagogues simultaneously does not necessarily triple GH output. GH pulse amplitude has a ceiling set by available somatotroph capacity and somatostatin feedback. Published studies examining multi-compound secretagogue combinations generally show diminishing returns above two compounds, with additional GI side effects from non-selective GHRPs.
- 4A substantial portion of apparent lean mass gained in GH secretagogue research is glycogen-associated water retention. Muscle cells expand as IGF-1 drives glycogen supercompensation. Studies relying on scale weight rather than DEXA scanning cannot distinguish this from actual muscle protein accrual, which has led to overestimation of anabolic effects in some community reports.
- 5Follistatin peptide fragments with claims of dramatic lean mass gains derive from myostatin-knockout mouse models, which have fundamentally different muscle physiology than wild-type animals or humans. No human RCT data exists for any follistatin variant in muscle hypertrophy, and the extrapolation from these animal models to human outcomes is not supported.
Evidence-Ranked Comparison
| Peptide | Evidence | |
|---|---|---|
#1CJC-1295 + Ipamorelin | Preliminary Evidence | Full Profile → |
#2IGF-1 LR3 | Preliminary Evidence | Full Profile → |
#3Tesamorelin | Strong Evidence | Full Profile → |
#4GHRP-6 | Preliminary Evidence | Full Profile → |
#5Sermorelin | Moderate Evidence | Full Profile → |
Detailed Peptide Profiles
CJC-1295 + Ipamorelin
Preliminary EvidenceResearch ChemicalGH SecretagoguePreliminaryA long-acting GHRH analogue plus selective secretagogue used to study GH-axis signaling and body composition endpoints
Small human studies describe sustained GH and IGF-1 changes after CJC-1295 administration, but they do not establish meaningful outcomes for muscle growth, energy, or performance claims. Ipamorelin is studied as a selective ghrelin-receptor secretagogue. Published evidence is insufficient to support claims for muscle growth, physique, or recovery outcomes in general populations.
- Human pharmacodynamic data on GH and IGF-1 elevation
- Mechanism is relatively well described
- Useful GH-axis body composition research model
- Ipamorelin selectivity avoids cortisol elevation
- No broad approved indication for muscle growth
- Outcome evidence is limited
- Endocrine effects can be consequential
- WADA prohibited in competitive sport
IGF-1 LR3
Preliminary EvidenceResearch ChemicalIGF-1PreclinicalA direct IGF-1 receptor agonist used to study anabolic signaling pathways
IGF-1 LR3 is a modified IGF-1 analog with reduced binding-protein affinity, extending its half-life. It activates IGF-1 receptors on muscle satellite cells. Published evidence is primarily from cell culture and animal studies; human clinical safety and efficacy data for muscle growth applications are absent. Theoretical oncogenic risk through IGF-1 receptor activation in cancer cells has not been systematically investigated in humans.
- Defined receptor mechanism
- Extended half-life from reduced binding protein affinity
- Direct IGF-1R activation research tool
- Zero published human safety or efficacy data for muscle applications
- Unknown long-term safety profile
- Theoretical oncogenic risk
- No approved indication
Tesamorelin
Strong EvidenceFDA ApprovedIndication-SpecificGH-AxisA well-defined example of indication-specific GH-axis evidence with controlled human data
Tesamorelin has controlled clinical evidence for a narrow, regulated lipodystrophy indication (FDA-approved as Egrifta for HIV-associated lipodystrophy). Phase 3 RCTs demonstrated 15-18 percent visceral adipose tissue reduction with concurrent lean mass preservation in that specific population. It does not validate off-label body-composition, anti-aging, or performance claims. Use is indication-specific and clinician-directed.
- FDA-approved for specific lipodystrophy indication
- Controlled Phase 3 human data in studied population
- Visceral fat reduction with lean mass preservation (indication-specific)
- Clearer evidence boundary than many secretagogues
- Narrow approved indication (HIV lipodystrophy)
- Not interchangeable with research secretagogue blends
- GH/IGF-1 axis monitoring relevant
- Not a cosmetic intervention
GHRP-6
Preliminary EvidenceResearch ChemicalGHRPNon-SelectiveA non-selective ghrelin-receptor agonist for GH-pulse pharmacodynamic research
GHRP-6 is a non-selective ghrelin-receptor agonist that produces GH pulses alongside cortisol and prolactin elevation and significant appetite stimulation. Its GH-releasing effect is well characterized in pharmacodynamic studies. The cortisol and hunger co-stimulation are well-documented side effects that limit research utility for body composition endpoints. No large human trials establish it for muscle growth outcomes.
- Strong GH pulse stimulation
- Well-characterized pharmacodynamic profile
- Useful comparison point for selective vs. non-selective GHRPs
- Non-selective: significant cortisol and prolactin co-elevation
- Pronounced appetite stimulation
- Less favorable profile than Ipamorelin for most research designs
- No approved indication
Sermorelin
Moderate EvidenceResearch ChemicalGHRH AnalogPrior FDA HistoryThe GHRH analog with the most established clinical safety record from its prior prescription history
Sermorelin has the most extensive human safety data of any GH secretagogue because it was FDA-approved and prescribed clinically for pediatric growth hormone deficiency, providing years of prescribing history and safety studies. It is no longer commercially available in that approved form in the US. Its body composition effects in adults with GH deficiency have been studied, providing the most clinical safety context of any GHRH analog. This evidence does not establish efficacy for muscle growth in healthy adults.
- Most human safety data of any GHRH analog from clinical prescription history
- Well-tolerated in pediatric and adult GH deficiency studies
- Useful clinical safety reference for GHRH class research
- Lower potency and shorter half-life than CJC-1295
- No longer approved; available as compounded research compound
- Not established for muscle growth in healthy adults
How to Choose the Right Peptide
| Your Goal | Best Choice |
|---|---|
| Studying GH-axis body composition with the most published human pharmacodynamic data | CJC-1295 + Ipamorelin literature |
| Studying IGF-1 receptor signaling and direct anabolic mechanism research | IGF-1 LR3 literature |
| Understanding the indication-specific GH-axis evidence benchmark | Tesamorelin (Egrifta) literature |
| Studying non-selective ghrelin-receptor pharmacology and comparing GHRP profiles | GHRP-6 vs Ipamorelin comparison literature |
Research Background
The GH-IGF-1 Axis: Mechanism of GH Secretagogues
Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) work together in a cascade that forms the biological foundation of anabolic muscle physiology. GH is secreted from the anterior pituitary gland in response to GHRH and ghrelin receptor signals. Once in circulation, GH acts directly on muscle tissue and simultaneously stimulates hepatic production of IGF-1. IGF-1 is the primary mediator of GH's anabolic effects: it binds the IGF-1 receptor on satellite cells (muscle stem cells) and myoblasts, activating the PI3K-Akt-mTOR signaling cascade that drives protein synthesis and promotes satellite cell proliferation. GH secretagogues increase the amplitude and frequency of natural GH pulses. Published pharmacodynamic studies document GH and IGF-1 elevation; body composition outcomes in human trials are more limited.
GHRH Analogs vs GHRP Compounds: Mechanism Differences
GH secretagogues fall into two mechanistic classes that act on different receptors in the pituitary. GHRH analogs (CJC-1295, Sermorelin, Tesamorelin) bind the GHRH receptor and directly stimulate GH-producing somatotroph cells. GHRPs (Ipamorelin, GHRP-6) bind the GHS-R, the endogenous ghrelin receptor. When both classes are combined, they produce synergistic GH release because they work through complementary pathways. The selectivity of the GHRP component matters: Ipamorelin avoids cortisol and prolactin co-elevation that non-selective GHRPs like GHRP-6 produce. This pharmacodynamic characterization is well established; whether combination protocols produce meaningful muscle growth in healthy humans has not been established through controlled trials.
The Somatopause: GH Decline in Aging
GH secretion declines by approximately 14 percent per decade after peak levels in puberty. By age 60, most adults secrete only 20-30 percent of the GH they produced at age 20. This decline is linked to loss of lean muscle mass (sarcopenia), increases in visceral adipose tissue, reduced bone density, and impaired recovery. The hypothesis driving much GH secretagogue research in aging populations is that restoring GH pulse patterns could attenuate sarcopenia. Tesamorelin's Phase 3 data in adults with lipodystrophy provides the clearest human evidence that GHRH analogs can improve body composition in a defined, approved indication. This evidence does not extend to healthy aging populations or muscle growth endpoints.
Insulin Timing and GH Secretagogue Pharmacodynamics
GH secretagogues are most effective in a low-insulin environment because insulin and GH are mutually antagonistic: elevated insulin suppresses GH release through somatostatin activation. Published pharmacodynamic studies examining GH pulse amplitude have therefore controlled for insulin levels by standardising the metabolic state of subjects, an important consideration when interpreting reported GH pulse amplitudes from those studies. This is a methodological context for reading published research, not a protocol recommendation.
IGF-1 LR3 vs Native IGF-1: Extended Half-Life Mechanism
Native IGF-1 has a half-life of approximately 10-12 minutes in its free form due to rapid binding by IGF-binding proteins (IGFBPs) in the bloodstream. IGF-1 LR3's modifications (Arg3 substitution and N-terminal extension) reduce IGFBP binding affinity, extending its circulating half-life to 20-30 hours. This extended half-life produces sustained IGF-1 receptor activation. IGF-1 DES (des-1-3 IGF-1) takes a different approach: removing the first three amino acids eliminates IGFBP binding and increases potency at the cost of a very short half-life. These are pharmacokinetic characteristics documented in in vitro and animal studies. Human safety data for either analog in muscle research applications is not published.
Body Composition Research Endpoints
Muscle growth research requires precise measurement tools: DEXA scanning to separate lean mass from fat mass, MRI for muscle volume, muscle biopsy for fiber type analysis, and strength testing for functional outcomes. GH secretagogue body composition studies that use only scale weight are limited in their interpretive value because GH also causes glycogen-associated water retention that can inflate apparent lean mass gains. Published human studies with GH secretagogues that include DEXA endpoints provide the most informative data for understanding whether changes represent actual muscle protein accrual.
Research & Educational Use Only: All peptides and compounds referenced in this guide are research chemicals documented for scientific education. This content does not constitute medical advice. All compounds should only be used for legitimate laboratory research in accordance with applicable laws. Consult a licensed physician or researcher before any use.
Common Research Protocol Mistakes
Running GH secretagogue research without tracking IGF-1 blood levels
GH secretagogues work specifically by raising IGF-1. Published human pharmacodynamic studies that evaluate GH secretagogue effects measure IGF-1 at baseline and at defined study intervals to determine whether the compound is producing meaningful axis activation. Research designs that do not include IGF-1 as an endpoint cannot establish whether GH elevation occurred, which limits interpretability of body composition or other outcome data.
Expecting contractile muscle gain without progressive overload training
GH secretagogues create an anabolic hormonal environment by raising IGF-1, but IGF-1-driven protein synthesis follows the mechanical stress signals from resistance training. Without that mechanical stimulus, elevated IGF-1 does not selectively drive skeletal muscle hypertrophy. Published research consistently identifies resistance training as a necessary cofactor for meaningful muscle protein accrual.
Treating IGF-1 LR3 as equivalent to approved growth factor therapies
IGF-1 LR3 has no published human safety or efficacy data for muscle growth applications. It is a research chemical with theoretical oncogenic risk through MET and IGF-1R activation in cancer cells. Comparing it to approved GH therapies or tesamorelin misrepresents the evidence hierarchy. Its research use requires appropriate scientific oversight and safety monitoring.
Using scale weight as the primary outcome measure in body composition research
GH secretagogues produce changes in fat mass, lean mass, and cellular hydration simultaneously. Scale weight cannot distinguish between these. DEXA scanning provides separate measurements of fat mass and lean mass with sufficient precision to detect meaningful changes. Research that tracks only scale weight cannot meaningfully characterize body composition effects.
Frequently Asked Questions
What GH secretagogue has the most human evidence?
Tesamorelin has the strongest human evidence for body composition, with FDA approval based on Phase 3 RCTs in adults with HIV-associated lipodystrophy. This is a specific, narrow indication. Sermorelin has the most clinical safety history from its prior prescription use for pediatric GH deficiency. CJC-1295 has Phase 2 pharmacodynamic data showing GH and IGF-1 elevation. None of these compounds have evidence establishing muscle growth in healthy adults.
Can GH secretagogues produce meaningful muscle growth without resistance training?
GH secretagogues create an anabolic hormonal environment by raising IGF-1, but IGF-1-driven protein synthesis is directional: it follows the mechanical stress signals provided by resistance training. Without the mechanical stimulus, elevated IGF-1 does not selectively drive skeletal muscle hypertrophy. Published body composition research consistently shows that resistance training is a necessary cofactor for meaningful muscle protein accrual from GH-axis interventions.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of approximately 30 minutes. CJC-1295 with DAC has a half-life of approximately 8 days because the DAC modification causes it to bind reversibly to albumin, acting as a depot from which it slowly releases. The longer-acting variant produces more sustained GH elevation in pharmacokinetic studies. These are pharmacokinetic differences documented in published studies; which approach is appropriate for a given research design depends on the GH pulsatility endpoint being studied.
What proportion of GH secretagogue-associated mass gains is glycogen and water?
A substantial portion of apparent lean mass gained during GH secretagogue research protocols reflects glycogen-associated water retention, not contractile protein. IGF-1 drives glycogen supercompensation in muscle cells, causing them to expand. Studies using body composition endpoints (DEXA, BIA) rather than scale weight provide more accurate separation of fat mass, lean mass, and hydration effects. Researchers tracking only scale weight cannot distinguish between these components.
Is Sermorelin safer than other GH peptides?
Sermorelin has the most extensive human safety data of any GH secretagogue from its prior FDA-approved prescribing history for pediatric GH deficiency. Years of prescribing and pediatric safety studies provide context not available for CJC-1295 or Ipamorelin. The tradeoff is reduced potency: its short half-life limits sustained GH elevation achievable compared to CJC-1295 DAC. This clinical history does not mean sermorelin is approved or established for body composition or muscle growth in healthy adults.
Research Peptide Vendor List
These are the research peptide vendors we track. Each supplier is scored on published certificate of analysis practice, independent testing, review record, and operating history. All compounds are sold for laboratory research use only.
- Kylo Peptides VerifiedBatch-level third-party COA3.9 from 12 reviews
- Biolongevity Labs VerifiedBatch-level third-party COA4.0 from 5 reviews
- MyBioSource VerifiedBatch-level third-party COA3.4 from 5 reviews
- Biotech Peptides VerifiedBatch-level third-party COA2.6 from 17 reviews
- AminoClub VerifiedBatch-level third-party COA3.0 from 3 reviews
- Core Peptides VerifiedBatch-level third-party COA3.0 from 3 reviews
Related Research Guides
Want to compare peptides interactively?
Use our interactive comparison tool or stack builder to design your research protocol.